Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inflammatory myofibroblastic tumor of the prostate.
Fukiage K, Fujita K, Toyoda S, Nishimoto M, Kikuchi T, Chikugo T, Yoshimura K, Esa A, Ito A, Uemura H. Fukiage K, et al. Among authors: esa a. IJU Case Rep. 2024 Jan 18;7(2):141-143. doi: 10.1002/iju5.12687. eCollection 2024 Mar. IJU Case Rep. 2024. PMID: 38440704 Free PMC article.
Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer.
Adomi S, Fujita K, Kita H, Kuwahara K, Akashi Y, Nishimoto M, Matsumura N, Sugimoto K, Minami T, Nozawa M, Yoshimura K, Tahara H, Hirayama A, Nishioka T, Esa A, Uemura H. Adomi S, et al. Among authors: esa a. Cancer Diagn Progn. 2023 Jul 3;3(4):484-490. doi: 10.21873/cdp.10244. eCollection 2023 Jul-Aug. Cancer Diagn Progn. 2023. PMID: 37405216 Free PMC article.
Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis.
Matsumura N, Fujita K, Nishimoto M, Yamamoto Y, Kuwahara K, Nagai Y, Minami T, Hatanaka Y, Nozawa M, Morimoto Y, Tahara H, Uejima S, Esa A, Hirayama A, Yoshimura K, Uemura H. Matsumura N, et al. Among authors: esa a. Front Oncol. 2021 Dec 21;11:769068. doi: 10.3389/fonc.2021.769068. eCollection 2021. Front Oncol. 2021. PMID: 34993133 Free PMC article.
Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients - A propensity scoring approach.
Nagao K, Matsuyama H, Nozawa M, Hara I, Nishioka T, Komura T, Esa A, Uejima S, Imanishi M, Uekado Y, Ogawa T, Kajikawa H, Uemura H. Nagao K, et al. Among authors: esa a. Asian J Urol. 2016 Jan;3(1):33-38. doi: 10.1016/j.ajur.2015.10.003. Epub 2015 Oct 31. Asian J Urol. 2016. PMID: 29264160 Free PMC article.
Procalcitonin as an indicator of urosepsis.
Sugimoto K, Adomi S, Koike H, Esa A. Sugimoto K, et al. Among authors: esa a. Res Rep Urol. 2013 Mar 26;5:77-80. doi: 10.2147/RRU.S42711. eCollection 2013. Res Rep Urol. 2013. PMID: 24400237 Free PMC article.
Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis.
Nozawa M, Inagaki T, Nagao K, Nishioka T, Komura T, Esa A, Kitagawa M, Imanishi M, Uekado Y, Ogawa T, Kajikawa H, Uejima S, Matsuyama H, Hara I, Uemura H. Nozawa M, et al. Among authors: esa a. Int J Clin Oncol. 2014 Aug;19(4):693-701. doi: 10.1007/s10147-013-0604-z. Epub 2013 Aug 3. Int J Clin Oncol. 2014. PMID: 23912936 Clinical Trial.
107 results